BACKGROUND AND PURPOSE
Enhanced thromboxane (TX) biosynthesis has previously been reported in the acute phase after ischemic stroke. We investigated whether enhanced urinary excretion of 11-dehydro-TXB2, a noninvasive index of platelet activation, was present in the chronic phase after a transient ischemic attack (TIA) or stroke, including intracerebral hemorrhage.
METHODS
We obtained a single urinary sample from 92 patients between 3 and 9 months after onset of stroke or TIA. The urinary excretion of the major enzymatic metabolite of TXA2, 11-dehydro-TXB2, was measured by a previously validated radioimmunoassay. The excretion rates were compared with those of 20 control patients with nonvascular neurological diseases.
RESULTS
Urinary 11-dehydro-TXB2 averaged 294+/-139, 413+/-419, and 557+/-432 pmol/mmol creatinine for patients with TIA, ischemic stroke, and intracerebral hemorrhage, respectively; the values were higher in all subgroups (P<0.01) than that in control patients (119+/-66 pmol/mmol). Increased 11-dehydro-TXB2 excretion was present in 59% of all patients, in 60% (P<0.001) of patients with TIA, in 56% (P<0.001) of patients with ischemic stroke, and in 73% (P<0.001) of patients with intracerebral hemorrhage. Atrial fibrillation, no aspirin use, and severity of symptoms at follow-up contributed independently to the level of 11-dehydro-TXB2 excretion in a multiple linear regression analysis.
CONCLUSIONS
Platelet activation is often present in patients in the chronic phase after stroke, including those with intracerebral hemorrhage. Persistent platelet activation, which is associated with atrial fibrillation and poor stroke outcome, can be substantially suppressed by aspirin treatment.
[1]
D. Grobbee,et al.
The Dutch Vascular Factors in Dementia Study: rationale and design
,
1997,
Journal of Neurology.
[2]
P. Koudstaal,et al.
Platelet activation and lipid peroxidation in patients with acute ischemic stroke.
,
1997,
Stroke.
[3]
G. Davı̀,et al.
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.
,
1997,
Circulation.
[4]
P. Koudstaal,et al.
Evidence for Episodic Platelet Activation in Acute Ischemic Stroke
,
1994,
Stroke.
[5]
P. Koudstaal,et al.
Increased Thromboxane Biosynthesis in Patients With Acute Cerebral Ischemia
,
1993,
Stroke.
[6]
G. Davı̀,et al.
Increased Thromboxane Biosynthesis in Type IIa Hypercholesterolemia
,
1992,
Circulation.
[7]
G. Davı̀,et al.
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
,
1990,
The New England journal of medicine.
[8]
R. Bloch,et al.
Interobserver agreement for the assessment of handicap in stroke patients.
,
1988,
Stroke.
[9]
G. FitzGerald,et al.
Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine.
,
1987,
Biochimica et biophysica acta.